Related Experiment Videos

[Disease modifying antirheumatic drugs with inhibitory effect on osteoclastogenesis]

Makoto Urushibara1

  • 1Department of Orthopaedic Surgery, Juntendo University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 17, 2005
PubMed

Insights

Leflunomide directly inhibits osteoclast differentiation by blocking NFATc1 induction, a key factor in autoimmune arthritis bone destruction. This finding highlights a new therapeutic target for managing bone loss in inflammatory conditions.

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Autoimmune arthritis causes significant bone destruction.
  • Current antirheumatic drugs' mechanisms on bone cells are not fully understood.
  • Osteoclasts are critical for bone resorption in arthritis.

Purpose of the Study:

  • To investigate the direct effect of leflunomide on osteoclast differentiation.
  • To determine if leflunomide targets osteoclasts or other immune cells in autoimmune arthritis.
  • To identify the molecular pathways involved in leflunomide's action on bone destruction.

Main Methods:

  • In vitro studies on osteoclast differentiation.
  • Analysis of NFATc1 induction.
  • Assessment of leflunomide's effect on RANKL-mediated pathways.

Main Results:

  • Leflunomide directly inhibits RANKL-mediated osteoclast differentiation.
  • The drug suppresses the induction of NFATc1, a master regulator of osteoclastogenesis.
  • This direct action on osteoclasts is a significant mechanism for reducing bone destruction.

Conclusions:

  • Leflunomide's direct inhibition of osteoclast differentiation is crucial for ameliorating bone destruction in autoimmune arthritis.
  • The RANKL-dependent NFATc1 induction pathway is a promising target for pharmacological interventions against arthritic bone destruction.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.